The CHF supports the reintroduction of pills into the scope of the remade Order. The omission of these from the current Order is an unfortunate regulatory oversight. Consumers implicitly trust the regulatory system to ensure any product made available to them undergoes rigorous assessment of...Read more
About Policy Submissions
We regularly make submissions to national level inquiries. If you are after a submission from earlier than listed here, please contact us.
We expect the primary impact of the reclassification for consumers will be a greater level of quality for Active Medical Devices in terms of reliability, safety and effectiveness. By putting these medical devices into a higher class they will undergo more rigorous assessment prior to becoming...Read more
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation has been formed with a patient-centred approach in mind.
CHF notes that this consultation’s scope is limited to the regulatory guidance in line with existing regulatory requirements, and not...Read more
CHF appreciates the opportunity to provide a comment in response to proposed changes to a number of definitions and the scope of the medical device regulatory framework in Australia.
At the heart of CHF’s policy agenda is patient-centred care. Our responses to the TGA’s consultation...Read more
This submission is prepared in the context of an imminent federal election. CHF will be putting out an election priorities document which sets out our proposed agenda for health reform for through to 2025.Read more
CHF is committed to the National Medicines Policy and in ensuring that all Australians have access to high quality, safe medicines and that all medicines should be used in line with the principles of the quality use of medicines.
CHF is keen to ensure the scheduling process is used to...Read more
CHF welcomed the Review of Medicines and Medical Device Regulation. Whilst we did not support all the recommended approach of removing the required pre-approval of therapeutic goods advertisements to a complaints-based system, we are pleased to work with the Therapeutic Goods Administration (TGA...Read more
CHF applauds the PSA’s renewed commitment to quality, safety, and meeting evolving community needs. We support the PSA’s intention to expand pharmacist roles but feel that this discussion paper has focused too much on community pharmacists and has overlooked the possibilities for hospital and...Read more
Consumer access to their own health records through My Health Record (MHR) is a key step in the shift from health consumers as passive patients, to consumers as active partners in their own care, exercising choice and control. It is vital that the goal of putting consumers at the centre of their...Read more
The Australian Medical Research Advisory Board sought reflections and feedback on the first set of priorities for the Medical Research Future Fund (the MRFF) via a survey. This submission details CHF’s responses to the key questions in the survey.Read more